Sangamo BioSciences | SGMO - Nettoeinkommen





Nettoeinkommen Veränderung Datum
Alaunos Therapeutics USD -1.01M 153K 2026-03
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
Alterity Therapeutics Limited AUD -6.3M 525.41K 2025-12
Amgen USD 1.82B 486M 2026-03
Bayer EUR 2.76B 6.52B 2026-03
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
Biogen USD 319.5M 368.4M 2026-03
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
Cipla INR 5.55B 1.21B 2026-03
Clal Biotechnology ILS -6.17M 15.56M 2022-12
Compugen USD 56.84M 63.82M 2025-12
CSL USD 401M 96.5M 2025-12
Gilead Sciences USD 2.02B 162M 2026-03
GlaxoSmithKline GBP 1.74B 1.1B 2026-03
Grifols EUR 114.37M 34.03M 2025-12
Ionis Pharmaceuticals USD -93M 136M 2026-03
J&J USD 5.24B 119M 2026-03
Karyopharm Therapeutics USD -102.2M 71.42M 2025-12
Merck USD -4.24B 7.2B 2026-03
Novartis USD 3.16B 747M 2026-03
Omeros USD -32.23M 23.81M 2024-09
Pfizer USD 2.69B 4.34B 2026-03
Roche Holding CHF 5.47B 1.76B 2025-12
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Sanofi EUR 1.61B 2.42B 2026-03
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
Tectonic Therapeutic USD -19.23M 186K 2025-12
Ultragenyx Pharmaceutical USD -185M 56M 2026-03
Vertex Pharmaceuticals USD 1.03B 159.7M 2026-03